Lung metastases are secondary pulmonary tumors resulting from hematogenous dissemination of malignant cells from a primary neoplasm to the lungs. Owing to their extensive capillary network, the lungs represent a frequent site of hematogenous metastatic spread and, after the liver, are the second most common site of distant metastasis. Pulmonary metastases may present as a solitary lesion, as oligometastatic disease involving 2-5 lesions, or as multiple metastatic deposits. The extent of metastatic disease is a key determinant of treatment strategy. In patients with oligometastatic pulmonary involvement, a curative-intent therapeutic approach may be feasible.
Lung metastases are frequently asymptomatic and are commonly detected during imaging-based oncological follow-up. Clinical symptoms generally develop only with increasing tumor burden or when lesions are situated in anatomically unfavorable locations.
Constitutional symptoms such as unintentional weight loss, fatigue, or reduced performance status are nonspecific but may occur in patients with pulmonary metastatic disease. Night sweats and low-grade fever may likewise be present.
Lung metastases are predominantly identified during structured oncological surveillance. The diagnostic objective is to characterize the pulmonary lesions precisely with regard to number, size, anatomical location, and their relationship to the bronchi and pulmonary vasculature, while also distinguishing metastatic disease from a second primary bronchogenic carcinoma.
Before any curative-intent local treatment, comprehensive restaging should be performed - including CT of the chest and abdomen and, where clinically indicated, PET/CT and brain MRI - to exclude additional metastatic manifestations.
Treatment of lung metastases is determined by the primary malignancy, number and size of pulmonary lesions, pulmonary functional reserve, and the patient's overall clinical condition. Therapeutic decisions are made on an interdisciplinary basis within a multidisciplinary tumor board.
Stereotactic body radiotherapy (SBRT) is a particularly well-established and effective treatment modality for pulmonary metastases. Using advanced respiratory motion management, the CyberKnife system can continuously track moving lung lesions in real time without requiring the patient to hold their breath.
At the European Radiosurgery Center Munich, we have been treating patients with pulmonary metastases from a broad spectrum of primary malignancies for more than 20 years. Each treatment is individually planned in close coordination with the patient's treating medical oncology and thoracic surgery teams.
For tumors that move with respiration - for example lesions in the lung, liver, or upper abdomen - the CyberKnife system uses a technology known as Synchrony.
Infrared LEDs or reflective markers are positioned on the patient's chest or abdomen. An infrared camerain the treatment room continuously records the movement of these external markers. At the same time, repeated X-ray images determine the actual position of the tumor or implanted fiducial markers within the body. The system uses these data to generate a correlation model linking external respiratory motion with internal tumor motion.
The robotic arm then dynamically adjusts the position of the linear accelerator in real time, allowing the radiation beam to remain precisely aligned with the tumor throughout the respiratory cycle.
Lung metastases arise when malignant cells from a primary tumor elsewhere in the body - for example colorectal, renal, or breast cancer - disseminate to the lungs. A primary bronchogenic carcinoma (lung cancer), by contrast, originates directly from the epithelial cells of the respiratory tract. Distinguishing between these entities is crucial for treatment selection and prognosis and may, in some cases, require histopathological confirmation by biopsy.
Particularly in patients with sarcomas or colorectal carcinoma and isolated pulmonary metastatic disease, treatment with curative intent may be feasible. Five-year survival rates of approximately 30-50% have been reported following complete resection or CyberKnife treatment in appropriately selected patients with oligometastatic disease. Even when cure is not achievable, durable local tumor control may still be obtained.
Yes. CyberKnife® treatment can target multiple pulmonary metastases within a single treatment course and, in selected cases, even during a single treatment session. Adequate pulmonary functional reserve is required because irradiation of each lesion inevitably exposes a small volume of surrounding lung parenchyma. The number of lesions that can be treated safely is therefore determined individually during treatment planning.
Particularly favorable clinical outcomes have been reported for pulmonary metastases from colorectal carcinoma, renal cell carcinoma, sarcomas, and head and neck malignancies. Melanoma metastases may likewise be effectively treated in an oligometastatic setting, particularly in combination with immunotherapy. Treatment efficacy depends on tumor biology, metastatic lesion size, and the prescribed radiation dose.
Treatment is performed on an outpatient basis and generally does not require prolonged restrictions in physical activity. Regular follow-up CT examinations are required after irradiation to assess treatment response. Radiation pneumonitis may transiently develop within the irradiated region; it is frequently asymptomatic or may present with mild cough. The timing and scope of all follow-up examinations are individualized.
It is important to us that you, your family members, and those close to you fully understand and are able to assess all relevant aspects of your disease and the available treatment options. Together with our medical partners, we accompany you throughout this process and ensure that you feel comprehensively cared for at the ERCM from the very beginning.
For treatment enquiries, please use the contact form. You may also contact us by telephone during our opening hours or through our social media channels.
Your enquiry will be reviewed individually and processed promptly.